Drug intelligence / Profile preview

zirconium Zr 89-DFO-RB6

Development stage: Unknown
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Zirconium Zr 89-DFO-RB6 is a radioimmunoconjugate consisting of the RB6 antibody labeled with zirconium-89 using desferrioxamine (DFO) as a chelator. It is designed for CD70-targeted immunoPET imaging of malignant cancers, including renal cancers, lymphomas, and nasopharyngeal carcinomas. The compound allows for visualization of CD70-expressing tumors through positron emission tomography (PET) imaging.

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on zirconium Zr 89-DFO-RB6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zirconium Zr 89-DFO-RB6.

Explore the full profile